Katrine Bosley appointed to Galapagos’ Board of Directors

Mechelen, Belgium; 4 March 2013 – Galapagos NV (Euronext: GLPG) announced today the appointment of Katrine Bosley to its Board of Directors as an independent Non-Executive Director.

Ms Bosley was appointed to fill the vacancy that has arisen on Galapagos’ Board as a result of the recent resignation of Mr Ferdinand Verdonck, who has been a member of the Galapagos Board since the IPO of the Company in 2005. 

“On behalf of the Board I sincerely thank Ferdinand for his exceptional support of the Company during the last eight years,” Raj Parekh, Chairman of the Board, commented.  “We all strongly appreciate Ferdinand’s material role as a Board member in guiding Galapagos in its evolution and transformation from a young biotech company into a mature bio-pharmaceutical group, and we are very grateful for his constructive and stimulating contributions over such a long period.”

Katrine Bosley was until recently the CEO of Avila Therapeutics, a targeted covalent drug company.  Avila established a number of strategic alliances prior to its acquisition by Celgene in 2012.  Prior to Avila, Katrine was Vice President Business Development at Adnexus Therapeutics, a company developing a new class of protein therapeutics. Katrine joined Adnexus from Biogen Idec where she had roles in business development, commercial operations, and portfolio strategy in the U.S. and Europe.  Earlier, she was part of the healthcare team at the venture firm Highland Capital Partners. Katrine graduated from Cornell University with a B.A. in biology and completed the Program for Management Development at Harvard Business School.

“We are very pleased that Katrine has agreed to become a member of the Galapagos Board of Directors.  Her proven track record of scientific and business leadership, as well as her specific expertise in matters that are of direct importance for the Company’s growth path, will make her an excellent Board member,” commented Onno van de Stolpe, CEO of Galapagos.

About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action, with a large pipeline of four clinical, six pre-clinical, and 30 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, antibiotics, metabolic disease, and other indications.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, about to enter Phase 2b studies.  AbbVie and Galapagos signed a worldwide license agreement whereby AbbVie will be responsible for further development and commercialization after Phase 2b.  Galapagos has another selective JAK1 inhibitor in Phase 2 in lupus and psoriasis, GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in 2012).  GLPG0187 is a novel integrin receptor antagonist currently in a Phase 1b patient study in metastasis.  GLPG0974 is the first inhibitor of GPR43 to be evaluated clinically for the treatment of IBD; this program will start a Proof of Concept Phase 2 study in Q2 2013.
The Galapagos Group, including fee-for-service companies BioFocus, Argenta and Fidelta, has over 800 employees and operates facilities in five countries, with global headquarters in Mechelen, Belgium.  Further information at: www.glpg.com


Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028

Galapagos forward-looking statements

This release may contain forward-looking statements, including, without limitation, statements containing the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,” “may,” “will,” “could,” “stands to,” and “continues,” as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.